Acute SSRI (selective serotonin reuptake inhibitor) treatment has been shown to attenuate the abuse-related effects of cocaine; however, SSRIs have had limited success in clinical trials for cocaine abuse, possibly due to neurobiological changes that occur during chronic administration. In order to better understand the role of serotonin (5HT) in cocaine abuse and treatment, we examined the effects of chronic treatment with the SSRI fluoxetine at clinically relevant serum concentrations on cocaine-related neurobiology and behavior. Rhesus macaques self-administering cocaine underwent a 6-week dosing regimen with fluoxetine designed to approximate serum concentrations observed in humans. Self-administration and reinstatement were monitored throughout the treatment and washout period. In vivo microdiaylsis was used to assess changes in dopaminergic and serotonergic neurochemistry. Positron emission tomography was used to assess changes in the 5HT transporter and 2A receptor binding potential (BP). Functional output of the 5HT system was assessed using prolactin levels. Cocaine-primed reinstatement and cocaine-elicited dopamine overflow were significantly suppressed following chronic fluoxetine treatment. 5HT2A receptor BP was increased in the frontal cortex following treatment while prolactin release was blunted, suggesting desensitization of the 5HT2A receptor. These effects persisted after a 6-week washout period. Measures of pre-synaptic serotonergic function and cocaine self-administration were unaffected. These data demonstrate that acute and chronic fluoxetine treatments exert different effects on cocaine-related behavior. Furthermore, chronic fluoxetine treatment causes alterations in 5HT2A receptors in the frontal cortex that may selectively disrupt cocaine-primed reinstatement. Fluoxetine may not be useful for treatment of ongoing cocaine abuse but may be useful in relapse prevention.
INTRODUCTION
Cocaine abuse is a serious problem, with 1.1 million abusers reported in 2009 (Substance Abuse and Mental Health Services Administration, 2010), yet there is currently no FDA-approved effective pharmacotherapy for cocaine addiction. While substitute agonist therapies are being considered (Howell and Wilcox, 2001a) , these medications often have high abuse potential. Different pharmacological targets should be considered; the serotonin (5HT) system, which modulates dopamine (DA), is one such target. Key brain areas involved in drug abuse, including the ventral tegemental area, the nucleus accumbens, and the prefrontal and frontal cortex, receive sertoneregic innervation. The serotonin 2A and 2C receptors have been implicated as likely candidates for mediating the influence of 5HT on DA neurotransmission (Bubar and Cunningham, 2008) .
Selective serotonin reuptake inhibitors (SSRIs) bind and block the serotonin transporter (SERT) and are currently approved to treat depression and mood disorders. Preclinically, they have been shown to attenuate the reinforcing (Carroll et al, 1990; Czoty et al, 2002) and reinstating (Baker et al, 2001; Ruedi-Bettschen et al, 2009 ) effects of cocaine in rodents and primates, although they may potentiate the discriminative-stimulus effects of low doses (Cunningham and Callahan, 1991; Schama et al, 1997) . In human laboratory studies, pretreatment with fluoxetine decreased ratings of cocaine's positive subjective effects (Walsh et al, 1994) . SSRIs also caused an acute increase in extracellular 5HT in rats (Kreiss and Lucki, 1995; Marek et al, 2005; Qu et al, 2009 ) and attenuated cocaine-induced increases in extracellular DA in nonhuman primates (Czoty et al, 2002) .
However, clinical trials testing SSRIs failed to show reductions in cocaine abuse (Grabowski et al, 1995; Schmitz et al, 2001; Winstanley et al, 2011) , although recently there has also been some success (Moeller et al, 2007; Oliveto et al, 2012) . This may be due in part to the different dosing regimens and end points employed by the various preclinical and clinical studies; preclinical studies generally employ single-dose treatments and evaluate end points related to cocaine pharmacology, whereas clinical studies administer the drug chronically and generally focus on reductions in current cocaine use. Furthermore, the therapeutic effects of SSRIs for depression and mood disorders do not emerge until 3-4 weeks after beginning treatment, and are believed to rely on neurobiological changes (Wong et al, 1995) . For example, 5HT levels are not elevated during chronic treatment (Smith et al, 2000) , ostensibly due to downregulation of the SERT (Benmansour et al, 1999; Kugaya et al, 2003) , and desensitization of the 5HT1A autoreceptor (Ceglia et al, 2004; Riad et al, 2008) , which do not occur during acute treatment. Neurobiological changes due to prolonged SSRI treatment may alter the effects of the SSRI on cocaine-related behavior and neurobiology. Additionally, the presence of cocaine-induced neurobiological changes, such as the sensitization of both DA and 5HT release in key areas of the mesolimbic system (Parsons and Justice, 1993) and upregulation of SERT (Banks et al, 2008; Mash et al, 2000) , could alter the effects of prolonged SSRI treatment.
We examined the effects of chronic treatment with the SSRI, fluoxetine, at serum concentrations comparable to clinically observed concentrations, on cocaine self-administration behavior and neurochemistry, as well as on 5HT neurobiology and functional integrity in rhesus macaques in order to better understand the neurobiological effects of SSRI treatment in the context of cocaine use, and their relationship to cocaine-related behavior. Such knowledge could lead to more appropriate and effective use of SSRIs in both preclinical and clinical applications, and implicate particular receptors and neurobiological changes in the success or failure of serotonergic compounds in the treatment of cocaine abuse. Fluoxetine was chosen since it is one of the most well-characterized SSRIs (Wong et al, 1995) , as well as the drug of choice for several clinical trials that examined SSRIs' effects on cocaine abuse (Grabowski et al, 1995; Schmitz et al, 2001; Winstanley et al, 2011) .
MATERIALS AND METHODS

Subjects
Adult rhesus macaques (macaca mulatta; n ¼ 9) served as subjects. Five females weighing 6-9 kg participated in experiments 1 and 2; four males weighing 12-16 kg participated in experiment 3 (Supplementary Information). All subjects were individually housed within a primate colony and fed Purina monkey chow supplemented with fruits and vegetables. Water was freely available. Each animal was implanted with a chronic indwelling subcutaneous access port (Access Technologies, Skokie, IL, USA) and venous catheter as described previously (Howell and Wilcox, 2001b) and had experience self-administering cocaine. All procedures and studies followed the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985) , and were approved by the Institutional Animal Care and Use Committee of Emory University.
Drugs
Cocaine HCl (National Institute on Drug Abuse, Rockville, MD, USA) was dissolved in 0.9% saline and diluted to the desired unit dose according to each individual's body weight. Fenfluramine, a 5HT releaser, was purchased from Sigma-Aldrich (St Louis, MO, USA) and dissolved in 0.9% saline. Fluoxetine HCl was purchased from Spectrum Chemicals and Laboratory Products (New Jersey, USA) and administered orally (10 mg/kg/day) for 42 days. Each animal's dose was individually weighed and mixed with peanut butter or other palatable substances.
Behavioral Paradigms
Self-administration. Subjects (n ¼ 9) were trained to selfadminister cocaine on a fixed ratio (FR) 20 response schedule of i.v. drug administration using an operant panel equipped with response levers and lights and controlled by a computer program (MedPC, MedAssociates, St Albans, VT, USA). Drug infusions, delivered by an automated syringe pump, were paired with brief illumination of a red light and followed with a 30-s timeout. Sessions occurred once a day and lasted until either 30 infusions had been earned or an hour had elapsed, whichever occurred first. Response rate served as a measure of reinforcing effects.
Reinstatement. Subjects underwent extinction training in which saline was substituted for cocaine in the syringe and the brief paired stimuli (lights) omitted until responding fell below 20% of previous response rate. At this point, reinstatement sessions were conducted by restoring the brief paired stimuli and priming the animal with a noncontingent dose of cocaine immediately before the session. Only saline was available during reinstatement sessions. Two doses of cocaine (0.01 and 0.03 mg/kg) and saline were tested in reinstatement and responding was extinguished between reinstatement sessions. Response rate during reinstatement sessions was normalized to the individual's cocaine selfadministration response rate before extinction.
Positron Emission Tomography
Subjects were anesthetized and scanned using [ 11 C]M100907 (Ito et al, 1998) (Stehouwer et al, 2008) to determine 5HT2A and SERT binding potential (BP), respectively, on separate occasions. Nondisplaceable BPs, BP ND , were calculated using the simplified reference tissue model (Lammertsma and Hume, 1996) and cerebellum reference region (Hinz et al, 2007; Kish et al, 2005) for the frontal cortex, midbrain/brainstem, and caudate nuclei (Supplementary Figure S1) . It is important to note that the cerebellum contains a low level of 5HT2A expression and thus low BPs reflect similar levels, as opposed to the absence of 5HT2A binding. Procedural details are reported in Supplementary Materials and Methods.
In Vivo Microdialysis and Prolactin Response
Subjects were surgically prepared with guide cannulae targeting the caudate nucleus before the start of any experimental measures but after cocaine self-administration training had been completed. Awake subjects underwent in vivo microdialysis sessions with cocaine (1.0 mg/kg, i.v.) and fenfluramine (3.0 mg/kg, i.v.) on separate occasions to determine the effects of treatment on the DA response to cocaine and the pre-synaptic function of the 5HT system, respectively. During fenfluramine-challenge sessions, animals also underwent blood sample collection; samples were frozen and later processed for prolactin, to assess the postsynaptic function of the 5HT system. Procedural details are reported in Supplementary Materials and Methods.
Experiment 1: Chronic Fluoxetine Treatment
Subjects (female; n ¼ 5) underwent chronic fluoxetine treatment designed to approximate serum concentrations observed in the human clinical setting as described elsewhere (Sawyer and Howell, 2011) . Briefly, fluoxetine (10 mg/kg/day, p.o.) was administered for 6 weeks, which has been previously demonstrated to achieve serum concentrations comparable to those reported in the human clinical condition (200-1000 ng/ml). This dosing regimen was chosen to maximize the translational relevance of the study, since the relationship between serum concentration and drug effects, particularly therapeutic effects for depression, are not well understood for SSRIs (Baumann, 1996) . Serum concentrations were monitored via weekly blood draws to ensure maintenance in the target range (200-1000 ng/ml; see Supplementary Materials and Methods for additional details). Each animal had a minimum of 1 year of experience self-administering cocaine before beginning experimental measures.
Cocaine dose-effect curves were determined in each individual by substituting different concentrations of cocaine in the syringe. The dose that engendered the highest response rates, or the peak dose, was selected for the following experiments (0.01 mg/kg/infusion for all subjects). Subjects were then stabilized on this dose (o20% variability in response rate across 5 days) before beginning SSRI treatment. This served as the baseline time point response rate for selfadministration. All neurobiological and behavioral baseline measures were collected after determination of the doseresponse curve and before beginning fluoxetine treatment. Fluoxetine treatment was administered in a block design (Figure 1 ) and lasted for 6 weeks (42 days), followed by a 6-week washout period. Each 6-week block consisted of 4 weeks of cocaine self-administration sessions, followed by a 2-week period of extinction and reinstatement testing. Average response rate across 5 days served as an indicator of reinforcing effects and was derived from the 5 days of week 4 in each block. At the end of each block, animals resumed daily self-administration testing, and 5HT and DA neurochemistry were assessed using in vivo microdialysis; 5HT function assessed using prolactin response; and SERT and 5HT2A availability assessed using PET imaging. All neurobiological assessments were conducted a minimum of 3-4 days following the end of fluoxetine treatment to ensure that observed effects would reflect alterations in neurobiology, not the direct effects of fluoxetine (Sawyer and Howell, 2011 ). An additional microdialysis session with a cocaine challenge was conducted during week 4 of chronic fluoxetine treatment to directly assess the effects of ongoing treatment on the response to cocaine. Details of data analysis are reported in Supplementary Materials and Methods.
RESULTS
Experiment 1: Chronic Fluoxetine Treatment
Cocaine-related behavior. Daily administration of 10 mg/ kg fluoxetine, p.o., sustained serum concentrations of active drug within the clinically reported range (200-1000 ng/ml; Supplementary Figure S2 ) (Sawyer and Howell, 2011) . Serum concentrations were consistently between 250-450 ng/ml during weeks 3-6 of treatment when all behavioral measures were determined.
Cocaine self-administration rates varied between individuals (average: 1.01 ± 0.46 presses/s; see Supplementary Figure S7 ); thus, rate data were normalized to the stable baseline average for each subject. All five subjects participated in the self-administration portion of the experiment; however, one animal failed to maintain a stable baseline rate and thus was not included in the behavioral analyses. No Figure 1 Experimental design for experiment 1, consisting of three 6-week blocks of cocaine self-administration and reinstatement testing, followed by neurochemical and neurobiological assessments (dark gray arrows). The light gray arrow indicates a single in vivo microdialysis session with cocaine challenge during fluoxetine treatment; all other testing at dark gray arrows is timed such that no SSRI would be present in the system. Total time for all three blocks is 18 weeks.
Effects of fluoxetine on the neurobiology of cocaine use EK Sawyer et al significant differences were seen between baseline, chronic fluoxetine treatment, and washout conditions (Figure 2a) . At the baseline time point, a dose of 0.01 mg/kg cocaine resulted in significant reinstatement of responding as compared with a saline prime (F(2,3) ¼ 4.94, p ¼ 0.05; Dunnet's multiple comparison po0.05; Figure 2b ) and 0.03 mg/kg resulted in responding above extinction levels. Both drug and nondrug primes were accompanied by restoring the brief paired stimuli; saline plus brief paired stimuli did not result in responding above extinction levels. Following chronic fluoxetine treatment, significant reinstatement was not observed and response rate remained at extinction levels for all doses of cocaine tested. This effect persisted after the 6-week washout period.
Cocaine-induced DA overflow. Two of the five animals implanted lost the cannula preparation before starting experiments; thus only three animals participated in the microdialysis studies in experiment 1. There was no difference between baseline DA dialysate levels (Supplementary Table S1 ) within individuals across the different study points, thus each data set was normalized to its respective baseline. All sessions demonstrated an increase in DA in response to high potassium challenge (average: baseline, 4235±3495%; mid-SSRI, 1754±1197%; post-SSRI, 2403± 982%; post-washout, 3684 ± 1884%), confirming site viability. Cocaine induced a significant increase in DA overflow in the caudate nucleus (main effect of time, F(17,34) ¼ 29.26, po0.001). There was no main effect of fluoxetine treatment, but there was a significant interaction between time and treatment (F(51,102) ¼ 1.65, p ¼ 0.016). Post hoc testing indicated that the DA overflow was significantly attenuated at 20 min post-injection (peak effect) during and immediately after fluoxetine treatment, and after the 6-week washout period (po0.05; Figure 3 ), indicating that chronic fluoxetine treatment resulted in a lasting attenuation of cocaine-induced increases in DA.
Serotonergic function. There was no difference between baseline 5HT dialysate levels between testing days (Supplementary Table S1 ), thus each data set was normalized to its respective baseline. All sessions demonstrated an increase in 5HT in response to high potassium challenge (average: baseline, 692±103%; post-SSRI, 2785±1553%; post-washout, 1402 ± 117%), confirming site viability. Fenfluramine induced significant increases in 5HT at all treatment stages as indicated by a main effect of time (F(17,85) ¼ 7.39, po0.0001; Figure 4a) ; however, chronic fluoxetine treatment had no effect on fenfluramine-induced 5HT overflow as measured by treatment main effect, peak effect, or area under the curve.
Baseline levels of prolactin did not differ between testing days (Supplementary Table S1 ), thus each data set was normalized to its respective baseline. Fenfluramine administration resulted in significant increases in serum prolactin levels at all treatment stages with a main effect for time (F(10,20) ¼ 19.36, po0.001; see Figure 4b ), a significant interaction with treatment (F(20,40) ¼ 2.29, p ¼ 0.013), and a trend toward a main effect of treatment (F(2,4) ¼ 4.563, p ¼ 0.09), indicating that prolactin release was blunted following fluoxetine treatment. Post hoc tests did not reveal significant pairwise comparisons at any time point. However, this lack of a statistically strong treatment effect may be due to high variability in the washout condition, during Figure 2 Cocaine self-administration and reinstatement before, during, and after washout of chronic fluoxetine treatment. (a) Average cocaine self-administration rates from week 4, normalized to baseline, for each phase of experiment 1 (n ¼ 4), and rates following acute fluoxetine treatment resulting in similar blood levels (Experiment 2, Supplementary Information) (n ¼ 3). (b) Cocaine-primed reinstatement for each phase of experiment 1 (n ¼ 4). Rates are depicted as percent of previous cocaine self-administration rate before extinction. *Indicates significance at po0.05. Figure 3 Dopamine levels in the caudate nucleus following cocaine challenge (1.0 mg/kg, i.v., at time 0; n ¼ 3). Peak overflow, at 20 min, is given in parentheses. Cocaine administration resulted in a significant increase in DA overflow for each stage, but peak levels were significantly reduced compared with baseline during fluoxetine treatment, immediately posttreatment, and remained suppressed following washout. *Indicates significance at po0.05.
which one animal's prolactin response recovered and the other two did not. Supplementary Table S2 . Chronic fluoxetine treatment had no effect on SERT BPs in the frontal cortex, midbrain/brainstem, or caudate (significant main effect for ROI, F(2,8) ¼ 21.01, po0.001; no significant treatment or interaction effect; Figure 5b ).
5HT2A and SERT BPs
DISCUSSION
This is the first study to examine the neurobiological changes underlying the effects of chronic fluoxetine treatment at clinically relevant concentrations in an animal model of cocaine abuse. Chronic fluoxetine treatment attenuated cocaine-primed reinstatement and cocaine-induced DA overflow, possibly through desensitization of 5HT2A receptors. Furthermore, these effects persist up to 6 weeks after the conclusion of fluoxetine treatment. However, chronic fluoxetine treatment did not disrupt ongoing cocaine self-administration behavior, and there was no effect on SERT availability or serotonin overflow.
Behavior and Neurochemistry
Previous preclinical work has demonstrated that acute administration of SSRIs attenuates cocaine self-administration (Carroll et al, 1990; Czoty et al, 2002) , reinstatement Figure 4 Serotonin (a) and prolactin (b) response to fenfluramine challenge (3.0 mg/kg, i.v. at time 0; n ¼ 3). There were no significant differences in 5HT response to fenfluramine challenge but prolactin was significantly blunted. (Baker et al, 2001; Ruedi-Bettschen et al, 2009) , and neurochemical effects (Czoty et al, 2002) . In the present study, chronic fluoxetine treatment suppressed cocaineprimed reinstatement, in agreement with the results of previous studies using acute pretreatments. Cocaineinduced DA overflow was also significantly attenuated during chronic treatment. However, this attenuation of cocaine's neurochemical effects did not affect ongoing cocaine selfadministration, which is in contrast to previous preclinical studies, but in concordance with clinical studies reporting no effect of fluoxetine treatment in human cocaine users (Grabowski et al, 1995; Schmitz et al, 2001; Winstanley et al, 2011) . The difference in effects between the current study and previous preclinical studies is unlikely to be due to differences in serum concentrations achieved by acute vs chronic dosing, since when chronic serum concentrations were matched using a single injection, fluoxetine significantly attenuated cocaine self-administration (see Supplementary Materials and Methods, experiment 2). Rather, it suggests the effects of chronic SSRI treatment in altering cocaine use may be mediated in part by neurobiological changes, as is hypothesized for the therapeutic effects of SSRIs in depression (Wong et al, 1995) . This is further supported by the observation that these effects persisted for 6 weeks following the conclusion of fluoxetine treatment.
Given the observed reductions in cocaine-induced DA overflow, it is somewhat surprising that cocaine selfadministration behavior was not affected. It is possible that the diminished DA response to cocaine was not due to fluoxetine treatment but rather the effects of long-term cocaine self-administration, as has been previously reported (Kirkland Henry et al, 2009) ; however, the decrease in cocaine-elicited DA reported in that study was observed in animals following the acquisition of cocaine self-administration, whereas the animals in the present study selfadministered cocaine for at least 1 year before beginning fluoxetine treatment. Furthermore, Kirkland Henry and colleagues reported no differences between limited-and extended-access to cocaine, suggesting that the changes in cocaine-elicited DA overflow were due to the initiation of cocaine self-administration and not due to long-term chronic use. A second possibility is that ongoing self-administration was more robust and difficult to disrupt compared with cocaine-induced reinstatement. A likely explanation is that the repeated dosing that occurs during self-administration sessions makes it possible to overcome a decrease in the reinforcing potency of a single injection, while the single, noncontingent dose that precedes reinstatement sessions does not.
Neurobiological Mechanisms
Given the prolonged changes in cocaine-related neurochemistry and behavior following chronic fluoxetine administration, we evaluated potential mechanisms underlying these changes by examining pre-and post-synaptic markers and function. There was no change in SERT BP in any of the brain areas examined immediately following chronic treatment or the 6-week washout period, and there was a corresponding lack of change in the magnitude and time course of 5HT overflow elicited by fenfluramine.
However, fenfluramine-induced prolactin release, measured concurrently, was blunted following chronic treatment. This has traditionally been used as a measure of integrated 5HT function or integrity (Newman et al, 1998) and although it may be influenced by menstrual cycle (O'Keane et al, 1991; Tanner et al, 2011) , individual data showed orderly decreases across study time points. Together, these data indicate that, while measures of presynaptic function were unchanged, there were altered downstream, post-synaptic effects.
The 5HT2A receptor has been extensively implicated in the reinstatement and discriminative-stimulus effects of cocaine (Filip et al, 2006; Fletcher et al, 2002) as well as in the antidepressant effects of SSRIs (Carr and Lucki, 2011) . Increased 5HT2A availability was observed in the frontal cortex following chronic treatment and 6 weeks post-treatment. This is unlikely to be due to changes in extracellular 5HT levels, which may compete with the radiotracer, as no changes in regulation of extracellular 5HT were observed. However, PET ligands are generally unable to detect desensitization of a receptor, and thus it is impossible to determine the functional status of a receptor solely with a PET scan. The 5HT2A receptor is involved in both mediating the prolactin response (Chaiseha et al, 2010; Jorgensen, 2007) and facilitating DA release (Bubar and Cunningham, 2008) ; therefore an increase in the prolactin response as well as in DA overflow would be expected. However, both the prolactin response and cocaine-induced DA overflow decreased with no change in the amount of 5HT overflow, suggesting that these receptors may in fact be desensitized. Agonist treatment is known to cause desensitization of 5HT2A receptors (Van Oekelen et al, 2003) , and this is further supported by data demonstrating reduced G-protein signaling in cells (Brink et al, 2004) , and reductions in 5HT2A-mediated corticosterone release in rats (Yamauchi et al, 2006) following chronic SSRI treatment. Therefore, it seems plausible that the decrease in prolactin response, cocaineinduced DA overflow, and thus, suppressed cocaine-induced reinstatement, may be due to desensitization of the 5HT2A receptor.
The continued suppression of cocaine-primed reinstatement and DA overflow even after 6 weeks of washout from the SSRI is a surprising and exciting finding. Although we hypothesize these effects to rely on the putative desensitization of the 5HT2A receptor, it is possible there is another underlying mechanism. Furthermore, it is unclear why the effects persist. The time course of recovery from desensitization for 5HT2A receptors is not known. Further investigations are needed to clarify the underlying mechanisms behind the maintenance of these effects.
SERT and 5HT2A Regulation
It is well accepted that chronic administration of SSRIs induces neurobiological changes but these have not been previously evaluated in the context of cocaine abuse, which also induces neurobiological changes (Koob and Volkow, 2010) . Our data demonstrate that, in contrast to previous reports of SERT downregulation by SSRIs (Benmansour et al, 1999; Kugaya et al, 2003) , prolonged fluoxetine treatment has no effect on SERT BPs in the context of ongoing cocaine use. Chronic exposure to cocaine has been shown to induce increases in SERT in primates (Banks et al, 2008; Mash et al, 2000) , and thus may oppose the effects of fluoxetine on SERT regulation. Since both compounds are reuptake inhibitors, it is not clear why they affect SERT regulation differently, but it may be due to different binding kinetics or actions at other serotonergic targets.
There is less of a consensus on regulation of the 5HT2A receptor, which has been reported to both upregulate and downregulate in response to SSRIs (Audenaert et al, 2006; Meyer et al, 2001 ). We report a significant increase in 5HT2A receptors in the frontal cortex following chronic fluoxetine treatment in the context of ongoing cocaine use, and furthermore, a similar increase following extended cocaine exposure alone (see Experiment 3, Supplementary Table S3 and Supplementary Materials and Methods for details and additional discussion). The effects of chronic cocaine and chronic SSRI treatment were not examined in the same animals, so it is not possible to say whether the increases may be additive. Furthermore, it is possible that since experiment 1 (fluoxetine) was conducted in females while experiment 3 (cocaine) was conducted in males, the findings may not generalize to females.
Clinical Implications
This study is the first to evaluate the effects of long-term, clinically relevant serum concentrations of fluoxetine on cocaine-related neurobiology and behavior and highlights the importance of evaluating potential treatments in the context of the target population. Although previous studies have demonstrated downregulation of SERT availability in noncocaine-using populations (Kugaya et al, 2003) , the results of our study suggest that this may not be the case for cocaine users and caution against the use of nondrug-using populations to predict results in drug-using populations. Furthermore, the lack of effect on ongoing self-administration behavior aligns with the results of clinical, rather than preclinical, studies, suggesting that the discrepancy in the results of these previous studies is due to differences in SSRI administration, underscoring the need to appropriately design preclinical studies to mirror the potential clinical usage of a treatment. Importantly, cocaine-primed reinstatement was suppressed, suggesting that while fluoxetine may not be effective as an intervention in ongoing cocaine abuse, it may be useful as an adjunct treatment to prevent relapse during initial or continuing abstinence, especially given the striking persistence of the effects after the conclusion of treatment. Indeed, to date only one study has examined the effects of SSRIs in preventing relapse in abstinent patients and found that treatment with sertraline delayed time to relapse in depressed cocaine-dependent patients (Oliveto et al, 2012) . Our results strongly suggest additional studies would be warranted.
